Forecast Of The Day: Boston Scientific Revenue From Cardiac Rhythm Management
What?
Boston Scientific (NYSE:BSX) Revenue from Cardiac Rhythm Management declined from around $1.9 billion in 2019 to around $1.7 billion in 2020. Trefis expects the metric to recover to about $2 billion in 2021 and $2.05 billion in 2022.
Why?
- What To Expect From Boston Scientific Stock Following Q2 Earnings?
- Should You Buy Boston Scientific Stock At $38?
- What’s Happening With Boston Scientific Stock?
- What To Expect From Boston Scientific Stock Following Q1 Earnings?
- This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
- Company Of The Day: Boston Scientific
While sales fell in 2020 due to the Covid-19 pandemic and the related decline in elective procedures, we expect sales to rebound in 2021 as Covid-19 vaccination rates improve. We expect longer-term growth to be driven by new product launches as well as expansion in emerging markets.
So What?
We don’t think the projected post-Covid recovery in Boston Scientific’s business is priced into its stock yet. We value BSX at about $50 per share, a premium of 12% over the current market price.
See Our Complete Analysis For BSX
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.